74 related articles for article (PubMed ID: 20736334)
1. Prevention of colitis-associated carcinogenesis with infliximab.
Kim YJ; Hong KS; Chung JW; Kim JH; Hahm KB
Cancer Prev Res (Phila); 2010 Oct; 3(10):1314-33. PubMed ID: 20736334
[TBL] [Abstract][Full Text] [Related]
2. Partial normalization of pubertal timing in female mice with DSS colitis treated with anti-TNF-α antibody.
Deboer MD; Steinman J; Li Y
J Gastroenterol; 2012 Jun; 47(6):647-54. PubMed ID: 22322660
[TBL] [Abstract][Full Text] [Related]
3. Black raspberries inhibit intestinal tumorigenesis in apc1638+/- and Muc2-/- mouse models of colorectal cancer.
Bi X; Fang W; Wang LS; Stoner GD; Yang W
Cancer Prev Res (Phila); 2010 Nov; 3(11):1443-50. PubMed ID: 21045162
[TBL] [Abstract][Full Text] [Related]
4. NAD metabolism fuels human and mouse intestinal inflammation.
Gerner RR; Klepsch V; Macheiner S; Arnhard K; Adolph TE; Grander C; Wieser V; Pfister A; Moser P; Hermann-Kleiter N; Baier G; Oberacher H; Tilg H; Moschen AR
Gut; 2018 Oct; 67(10):1813-1823. PubMed ID: 28877980
[TBL] [Abstract][Full Text] [Related]
5. Locally injected Infliximab ameliorates murine DSS colitis: differences in serum and intestinal levels of drug between healthy and colitic mice.
Lopetuso LR; Petito V; Cufino V; Arena V; Stigliano E; Gerardi V; Gaetani E; Poscia A; Amato A; Cammarota G; Papa A; Sgambato A; Gasbarrini A; Scaldaferri F
Dig Liver Dis; 2013 Dec; 45(12):1017-21. PubMed ID: 23911613
[TBL] [Abstract][Full Text] [Related]
6. Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review).
Ogurchenok NE; Khalin KD; Bryukhovetskiy IS
Med Int (Lond); 2024; 4(3):25. PubMed ID: 38628384
[TBL] [Abstract][Full Text] [Related]
7. Overcoming cancer risk in inflammatory bowel disease: new insights into preventive strategies and pathogenesis mechanisms including interactions of immune cells, cancer signaling pathways, and gut microbiota.
Zhang H; Shi Y; Lin C; He C; Wang S; Li Q; Sun Y; Li M
Front Immunol; 2023; 14():1338918. PubMed ID: 38288125
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases as biomarkers and therapeutic targets in colitis-associated cancer.
Sampaio Moura N; Schledwitz A; Alizadeh M; Patil SA; Raufman JP
Front Oncol; 2023; 13():1325095. PubMed ID: 38288108
[TBL] [Abstract][Full Text] [Related]
9. New sights of immunometabolism and agent progress in colitis associated colorectal cancer.
Zhang J; Chen C; Yan W; Fu Y
Front Pharmacol; 2023; 14():1303913. PubMed ID: 38273841
[TBL] [Abstract][Full Text] [Related]
10. Exploiting innate immunity for cancer immunotherapy.
Yi M; Li T; Niu M; Mei Q; Zhao B; Chu Q; Dai Z; Wu K
Mol Cancer; 2023 Nov; 22(1):187. PubMed ID: 38008741
[TBL] [Abstract][Full Text] [Related]
11. GPR4 Knockout Attenuates Intestinal Inflammation and Forestalls the Development of Colitis-Associated Colorectal Cancer in Murine Models.
Marie MA; Sanderlin EJ; Hoffman AP; Cashwell KD; Satturwar S; Hong H; Sun Y; Yang LV
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894341
[TBL] [Abstract][Full Text] [Related]
12. SCF and IL-33 regulate mouse mast cell phenotypic and functional plasticity supporting a pro-inflammatory microenvironment.
Molfetta R; Lecce M; Milito ND; Putro E; Pietropaolo G; Marangio C; Scarno G; Moretti M; De Smaele E; Santini T; Bernardini G; Sciumè G; Santoni A; Paolini R
Cell Death Dis; 2023 Sep; 14(9):616. PubMed ID: 37730723
[TBL] [Abstract][Full Text] [Related]
13. Infliximab Inhibits Colitis Associated Cancer in Model Mice by Downregulating Genes Associated with Mast Cells and Decreasing Their Accumulation.
Wang DY; Ohnuma S; Suzuki H; Ishida M; Ishii K; Hirosawa T; Hirashima T; Murakami M; Kobayashi M; Kudoh K; Haneda S; Musha H; Naitoh T; Unno M
Curr Issues Mol Biol; 2023 Apr; 45(4):2895-2907. PubMed ID: 37185713
[TBL] [Abstract][Full Text] [Related]
14. The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer.
He L; Kang Q; Chan KI; Zhang Y; Zhong Z; Tan W
Front Immunol; 2022; 13():1093990. PubMed ID: 36776395
[TBL] [Abstract][Full Text] [Related]
15. Genetically proxied inhibition of tumor necrosis factor and the risk of colorectal cancer: A drug-target mendelian randomization study.
Chen M; Chen Q; Xiao XY; Feng SJ; Wang XY; Tang TC; Zheng H
Front Pharmacol; 2022; 13():1079953. PubMed ID: 36618924
[No Abstract] [Full Text] [Related]
16. Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel Disease.
Hsiao SW; Yen HH; Chen YY
Gut Liver; 2022 Nov; 16(6):840-848. PubMed ID: 35670121
[TBL] [Abstract][Full Text] [Related]
17. Amelioration of cancer cachexia with preemptive administration of tumor necrosis factor-α blocker.
Kang EA; Park JM; Jin W; Tchahc H; Kwon KA; Hahm KB
J Clin Biochem Nutr; 2022 Mar; 70(2):117-128. PubMed ID: 35400817
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention.
Lucafò M; Curci D; Franzin M; Decorti G; Stocco G
Front Pharmacol; 2021; 12():772101. PubMed ID: 34744751
[TBL] [Abstract][Full Text] [Related]
19. Mast Cells: A New Frontier for Cancer Immunotherapy.
Lichterman JN; Reddy SM
Cells; 2021 May; 10(6):. PubMed ID: 34063789
[TBL] [Abstract][Full Text] [Related]
20. Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer.
Wang Y; Ding Y; Deng Y; Zheng Y; Wang S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
